#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The World Health Organization ( WHO ) classifies gliomas into four categories based on malignancy and overall survival ( OS ) .
3-1	17-20	The	organization[3]	new[3]	_	_
3-2	21-26	World	organization[3]	new[3]	_	_
3-3	27-33	Health	organization[3]	new[3]	_	_
3-4	34-46	Organization	organization[3]	new[3]	_	_
3-5	47-48	(	_	_	_	_
3-6	49-52	WHO	_	_	_	_
3-7	53-54	)	_	_	_	_
3-8	55-65	classifies	_	_	_	_
3-9	66-73	gliomas	object	new	_	_
3-10	74-78	into	_	_	_	_
3-11	79-83	four	abstract[5]	new[5]	_	_
3-12	84-94	categories	abstract[5]	new[5]	_	_
3-13	95-100	based	_	_	_	_
3-14	101-103	on	_	_	_	_
3-15	104-114	malignancy	abstract	new	coref	16-13[126_0]
3-16	115-118	and	_	_	_	_
3-17	119-126	overall	event[7]	new[7]	coref	5-14[0_7]
3-18	127-135	survival	event[7]	new[7]	_	_
3-19	136-137	(	_	_	_	_
3-20	138-140	OS	_	_	_	_
3-21	141-142	)	_	_	_	_
3-22	143-144	.	_	_	_	_

#Text=Glioblastoma is the most malignant form of astrocytoma that is fast-growing ( grade 4 glioma ) .
4-1	145-157	Glioblastoma	abstract	new	coref	4-3[9_0]
4-2	158-160	is	_	_	_	_
4-3	161-164	the	abstract[9]	giv[9]	coref	5-5[0_9]
4-4	165-169	most	abstract[9]	giv[9]	_	_
4-5	170-179	malignant	abstract[9]	giv[9]	_	_
4-6	180-184	form	abstract[9]	giv[9]	_	_
4-7	185-187	of	abstract[9]	giv[9]	_	_
4-8	188-199	astrocytoma	abstract[9]|abstract	giv[9]|new	_	_
4-9	200-204	that	_	_	_	_
4-10	205-207	is	_	_	_	_
4-11	208-220	fast-growing	_	_	_	_
4-12	221-222	(	_	_	_	_
4-13	223-228	grade	abstract|abstract[12]	new|new[12]	coref|coref	13-25[0_12]|13-25[0_12]
4-14	229-230	4	abstract[12]	new[12]	_	_
4-15	231-237	glioma	abstract[12]	new[12]	_	_
4-16	238-239	)	_	_	_	_
4-17	240-241	.	_	_	_	_

#Text=The median OS of glioblastoma is 9 – 15 months and the five-year survival rate remains less than 5 % .
5-1	242-245	The	abstract[13]	new[13]	coref	22-20[0_13]
5-2	246-252	median	abstract[13]	new[13]	_	_
5-3	253-255	OS	abstract[13]	new[13]	_	_
5-4	256-258	of	abstract[13]	new[13]	_	_
5-5	259-271	glioblastoma	abstract[13]|object	new[13]|giv	coref	7-21
5-6	272-274	is	_	_	_	_
5-7	275-276	9	time[15]	new[15]	_	_
5-8	277-278	–	time[15]	new[15]	_	_
5-9	279-281	15	time[15]|time[16]	new[15]|new[16]	_	_
5-10	282-288	months	time[15]|time[16]	new[15]|new[16]	_	_
5-11	289-292	and	_	_	_	_
5-12	293-296	the	abstract[18]	new[18]	_	_
5-13	297-306	five-year	abstract[18]	new[18]	_	_
5-14	307-315	survival	event|abstract[18]	giv|new[18]	coref	23-6[197_0]
5-15	316-320	rate	abstract[18]	new[18]	_	_
5-16	321-328	remains	_	_	_	_
5-17	329-333	less	quantity[19]	new[19]	_	_
5-18	334-338	than	quantity[19]	new[19]	_	_
5-19	339-340	5	quantity[19]	new[19]	_	_
5-20	341-342	%	quantity[19]	new[19]	_	_
5-21	343-344	.	_	_	_	_

#Text=Radiotherapy with six cycles of concomitant temozolomide , an oral alkylating agent with minimal additional toxicity , is the standard treatment after surgery in glioblastoma patients .
6-1	345-357	Radiotherapy	abstract[20]	new[20]	coref	6-19[25_20]
6-2	358-362	with	abstract[20]	new[20]	_	_
6-3	363-366	six	abstract[20]|event[21]	new[20]|new[21]	_	_
6-4	367-373	cycles	abstract[20]|event[21]	new[20]|new[21]	_	_
6-5	374-376	of	abstract[20]|event[21]	new[20]|new[21]	_	_
6-6	377-388	concomitant	abstract[20]|event[21]|substance[22]	new[20]|new[21]|new[22]	coref	17-3[0_22]
6-7	389-401	temozolomide	abstract[20]|event[21]|substance[22]	new[20]|new[21]|new[22]	_	_
6-8	402-403	,	_	_	_	_
6-9	404-406	an	person[23]	new[23]	_	_
6-10	407-411	oral	person[23]	new[23]	_	_
6-11	412-422	alkylating	person[23]	new[23]	_	_
6-12	423-428	agent	person[23]	new[23]	_	_
6-13	429-433	with	person[23]	new[23]	_	_
6-14	434-441	minimal	person[23]|abstract[24]	new[23]|new[24]	_	_
6-15	442-452	additional	person[23]|abstract[24]	new[23]|new[24]	_	_
6-16	453-461	toxicity	person[23]|abstract[24]	new[23]|new[24]	_	_
6-17	462-463	,	_	_	_	_
6-18	464-466	is	_	_	_	_
6-19	467-470	the	abstract[25]	giv[25]	_	_
6-20	471-479	standard	abstract[25]	giv[25]	_	_
6-21	480-489	treatment	abstract[25]	giv[25]	_	_
6-22	490-495	after	abstract[25]	giv[25]	_	_
6-23	496-503	surgery	abstract[25]|event[26]	giv[25]|new[26]	_	_
6-24	504-506	in	abstract[25]|event[26]	giv[25]|new[26]	_	_
6-25	507-519	glioblastoma	abstract[25]|event[26]|person[27]	giv[25]|new[26]|new[27]	coref	22-22[194_27]
6-26	520-528	patients	abstract[25]|event[26]|person[27]	giv[25]|new[26]|new[27]	_	_
6-27	529-530	.	_	_	_	_

#Text=Thus , there is an immediate requirement for the early diagnosis and precise prediction of the prognosis for treatments of glioblastoma .
7-1	531-535	Thus	_	_	_	_
7-2	536-537	,	_	_	_	_
7-3	538-543	there	_	_	_	_
7-4	544-546	is	_	_	_	_
7-5	547-549	an	abstract[28]	new[28]	_	_
7-6	550-559	immediate	abstract[28]	new[28]	_	_
7-7	560-571	requirement	abstract[28]	new[28]	_	_
7-8	572-575	for	abstract[28]	new[28]	_	_
7-9	576-579	the	abstract[28]|abstract[29]	new[28]|new[29]	_	_
7-10	580-585	early	abstract[28]|abstract[29]	new[28]|new[29]	_	_
7-11	586-595	diagnosis	abstract[28]|abstract[29]	new[28]|new[29]	_	_
7-12	596-599	and	abstract[28]	new[28]	_	_
7-13	600-607	precise	abstract[28]|event[30]	new[28]|new[30]	coref	23-14[0_30]
7-14	608-618	prediction	abstract[28]|event[30]	new[28]|new[30]	_	_
7-15	619-621	of	abstract[28]|event[30]	new[28]|new[30]	_	_
7-16	622-625	the	abstract[28]|event[30]|abstract[31]	new[28]|new[30]|new[31]	coref	23-13[0_31]
7-17	626-635	prognosis	abstract[28]|event[30]|abstract[31]	new[28]|new[30]|new[31]	_	_
7-18	636-639	for	abstract[28]|event[30]|abstract[31]	new[28]|new[30]|new[31]	_	_
7-19	640-650	treatments	abstract[28]|event[30]|abstract[31]|abstract[32]	new[28]|new[30]|new[31]|new[32]	_	_
7-20	651-653	of	abstract[28]|event[30]|abstract[31]|abstract[32]	new[28]|new[30]|new[31]|new[32]	_	_
7-21	654-666	glioblastoma	abstract[28]|event[30]|abstract[31]|abstract[32]|abstract	new[28]|new[30]|new[31]|new[32]|giv	coref	8-4
7-22	667-668	.	_	_	_	_

#Text=The invasiveness of glioblastoma depends on its high infiltration potential to invade the basement membranes of surrounding tissues .
8-1	669-672	The	abstract[34]	new[34]	_	_
8-2	673-685	invasiveness	abstract[34]	new[34]	_	_
8-3	686-688	of	abstract[34]	new[34]	_	_
8-4	689-701	glioblastoma	abstract[34]|abstract	new[34]|giv	ana	8-7
8-5	702-709	depends	_	_	_	_
8-6	710-712	on	_	_	_	_
8-7	713-716	its	abstract|abstract[38]	giv|new[38]	coref|coref	21-10|21-10
8-8	717-721	high	abstract[38]	new[38]	_	_
8-9	722-734	infiltration	abstract|abstract[38]	new|new[38]	_	_
8-10	735-744	potential	abstract[38]	new[38]	_	_
8-11	745-747	to	_	_	_	_
8-12	748-754	invade	_	_	_	_
8-13	755-758	the	place[40]	new[40]	coref	11-23[67_40]
8-14	759-767	basement	place|place[40]	new|new[40]	coref	11-24
8-15	768-777	membranes	place[40]	new[40]	_	_
8-16	778-780	of	place[40]	new[40]	_	_
8-17	781-792	surrounding	place[40]|place[41]	new[40]|new[41]	coref	18-29[155_41]
8-18	793-800	tissues	place[40]|place[41]	new[40]|new[41]	_	_
8-19	801-802	.	_	_	_	_

#Text=Glioma cells are reprogrammed to have increased motility via weakened cell adhesions and a dysregulated cytoskeleton ; this is known as epithelial – mesenchymal transition ( EMT ) .
9-1	803-809	Glioma	object[42]	new[42]	coref	11-1[0_42]
9-2	810-815	cells	object[42]	new[42]	_	_
9-3	816-819	are	_	_	_	_
9-4	820-832	reprogrammed	_	_	_	_
9-5	833-835	to	_	_	_	_
9-6	836-840	have	_	_	_	_
9-7	841-850	increased	abstract[43]	new[43]	ana	9-18[0_43]
9-8	851-859	motility	abstract[43]	new[43]	_	_
9-9	860-863	via	abstract[43]	new[43]	_	_
9-10	864-872	weakened	abstract[43]|abstract[45]	new[43]|new[45]	_	_
9-11	873-877	cell	abstract[43]|place|abstract[45]	new[43]|new|new[45]	coref	10-9
9-12	878-887	adhesions	abstract[43]|abstract[45]	new[43]|new[45]	_	_
9-13	888-891	and	abstract[43]	new[43]	_	_
9-14	892-893	a	abstract[43]|abstract[46]	new[43]|new[46]	_	_
9-15	894-906	dysregulated	abstract[43]|abstract[46]	new[43]|new[46]	_	_
9-16	907-919	cytoskeleton	abstract[43]|abstract[46]	new[43]|new[46]	_	_
9-17	920-921	;	_	_	_	_
9-18	922-926	this	abstract	giv	_	_
9-19	927-929	is	_	_	_	_
9-20	930-935	known	_	_	_	_
9-21	936-938	as	_	_	_	_
9-22	939-949	epithelial	_	_	_	_
9-23	950-951	–	_	_	_	_
9-24	952-963	mesenchymal	time|event[49]	new|new[49]	appos|coref|appos|coref	9-27[0_49]|10-19|9-27[0_49]|10-19
9-25	964-974	transition	event[49]	new[49]	_	_
9-26	975-976	(	_	_	_	_
9-27	977-980	EMT	event	giv	coref	10-1
9-28	981-982	)	_	_	_	_
9-29	983-984	.	_	_	_	_

#Text=EMT is a biological process that polarized epithelial cell sheets undergo , wherein multiple biochemical changes culminate in mesenchymal phenotypes .
10-1	985-988	EMT	abstract	giv	coref	10-3[52_0]
10-2	989-991	is	_	_	_	_
10-3	992-993	a	abstract[52]	giv[52]	coref	12-1[0_52]
10-4	994-1004	biological	abstract[52]	giv[52]	_	_
10-5	1005-1012	process	abstract[52]	giv[52]	_	_
10-6	1013-1017	that	_	_	_	_
10-7	1018-1027	polarized	_	_	_	_
10-8	1028-1038	epithelial	object[54]	new[54]	_	_
10-9	1039-1043	cell	object|object[54]	giv|new[54]	coref	11-17
10-10	1044-1050	sheets	object[54]	new[54]	_	_
10-11	1051-1058	undergo	_	_	_	_
10-12	1059-1060	,	_	_	_	_
10-13	1061-1068	wherein	_	_	_	_
10-14	1069-1077	multiple	abstract[55]	new[55]	coref	19-3[160_55]
10-15	1078-1089	biochemical	abstract[55]	new[55]	_	_
10-16	1090-1097	changes	abstract[55]	new[55]	_	_
10-17	1098-1107	culminate	_	_	_	_
10-18	1108-1110	in	_	_	_	_
10-19	1111-1122	mesenchymal	animal|abstract[57]	giv|new[57]	coref|coref|coref|coref	13-6[0_57]|13-32|13-6[0_57]|13-32
10-20	1123-1133	phenotypes	abstract[57]	new[57]	_	_
10-21	1134-1135	.	_	_	_	_

#Text=Cells display altered morphology , resistance to chemotherapy , and anoikis ( a form of programmed cell death of cells detached from the basement membranes ) .
11-1	1136-1141	Cells	object	giv	coref	11-20
11-2	1142-1149	display	_	_	_	_
11-3	1150-1157	altered	abstract[59]	new[59]	_	_
11-4	1158-1168	morphology	abstract[59]	new[59]	_	_
11-5	1169-1170	,	_	_	_	_
11-6	1171-1181	resistance	abstract[60]	new[60]	_	_
11-7	1182-1184	to	abstract[60]	new[60]	_	_
11-8	1185-1197	chemotherapy	abstract[60]|substance	new[60]|new	_	_
11-9	1198-1199	,	_	_	_	_
11-10	1200-1203	and	_	_	_	_
11-11	1204-1211	anoikis	abstract	new	_	_
11-12	1212-1213	(	_	_	_	_
11-13	1214-1215	a	event[64]	new[64]	_	_
11-14	1216-1220	form	event[64]	new[64]	_	_
11-15	1221-1223	of	event[64]	new[64]	_	_
11-16	1224-1234	programmed	event[64]	new[64]	_	_
11-17	1235-1239	cell	place|event[64]	giv|new[64]	coref	17-27
11-18	1240-1245	death	event[64]	new[64]	_	_
11-19	1246-1248	of	event[64]	new[64]	_	_
11-20	1249-1254	cells	event[64]|object	new[64]|giv	coref	13-25[90_0]
11-21	1255-1263	detached	_	_	_	_
11-22	1264-1268	from	_	_	_	_
11-23	1269-1272	the	place[67]	giv[67]	_	_
11-24	1273-1281	basement	place|place[67]	giv|giv[67]	_	_
11-25	1282-1291	membranes	place[67]	giv[67]	_	_
11-26	1292-1293	)	_	_	_	_
11-27	1294-1295	.	_	_	_	_

#Text=EMT is also involved in other biological processes , including implantation and embryo development , wound healing , tissue regeneration , and neoplasia associated with cancer progression .
12-1	1296-1299	EMT	abstract	giv	coref	13-10
12-2	1300-1302	is	_	_	_	_
12-3	1303-1307	also	_	_	_	_
12-4	1308-1316	involved	_	_	_	_
12-5	1317-1319	in	_	_	_	_
12-6	1320-1325	other	abstract[69]	new[69]	_	_
12-7	1326-1336	biological	abstract[69]	new[69]	_	_
12-8	1337-1346	processes	abstract[69]	new[69]	_	_
12-9	1347-1348	,	abstract[69]	new[69]	_	_
12-10	1349-1358	including	abstract[69]	new[69]	_	_
12-11	1359-1371	implantation	abstract[69]|event	new[69]|new	_	_
12-12	1372-1375	and	abstract[69]	new[69]	_	_
12-13	1376-1382	embryo	abstract[69]|substance|event[72]	new[69]|new|new[72]	_	_
12-14	1383-1394	development	abstract[69]|event[72]	new[69]|new[72]	_	_
12-15	1395-1396	,	abstract[69]	new[69]	_	_
12-16	1397-1402	wound	abstract[69]|abstract|event[74]	new[69]|new|new[74]	_	_
12-17	1403-1410	healing	abstract[69]|event[74]	new[69]|new[74]	_	_
12-18	1411-1412	,	abstract[69]	new[69]	_	_
12-19	1413-1419	tissue	abstract[69]|object|abstract[76]	new[69]|new|new[76]	_	_
12-20	1420-1432	regeneration	abstract[69]|abstract[76]	new[69]|new[76]	_	_
12-21	1433-1434	,	abstract[69]	new[69]	_	_
12-22	1435-1438	and	abstract[69]	new[69]	_	_
12-23	1439-1448	neoplasia	abstract[69]|abstract	new[69]|new	_	_
12-24	1449-1459	associated	_	_	_	_
12-25	1460-1464	with	_	_	_	_
12-26	1465-1471	cancer	abstract|abstract[79]	new|new[79]	coref|coref|coref|coref	13-4|20-1[171_79]|13-4|20-1[171_79]
12-27	1472-1483	progression	abstract[79]	new[79]	_	_
12-28	1484-1485	.	_	_	_	_

#Text=During invasion in cancer , phenotypes also change as EMT is mainly induced by hypoxia and the transforming growth factor ( TGF)-β released from glioma stem cells ( GSCs ) , mesenchymal stem cells ( MSCs ) , and myeloid cells recruited by hypoxia .
13-1	1486-1492	During	_	_	_	_
13-2	1493-1501	invasion	event[80]	new[80]	_	_
13-3	1502-1504	in	event[80]	new[80]	_	_
13-4	1505-1511	cancer	event[80]|abstract	new[80]|giv	coref	15-5
13-5	1512-1513	,	_	_	_	_
13-6	1514-1524	phenotypes	abstract	giv	_	_
13-7	1525-1529	also	_	_	_	_
13-8	1530-1536	change	_	_	_	_
13-9	1537-1539	as	_	_	_	_
13-10	1540-1543	EMT	event	giv	coref	21-6
13-11	1544-1546	is	_	_	_	_
13-12	1547-1553	mainly	_	_	_	_
13-13	1554-1561	induced	_	_	_	_
13-14	1562-1564	by	_	_	_	_
13-15	1565-1572	hypoxia	abstract	new	coref	13-44
13-16	1573-1576	and	_	_	_	_
13-17	1577-1580	the	abstract[86]	new[86]	appos	13-22[0_86]
13-18	1581-1593	transforming	abstract[86]	new[86]	_	_
13-19	1594-1600	growth	abstract|abstract[86]	new|new[86]	_	_
13-20	1601-1607	factor	abstract[86]	new[86]	_	_
13-21	1608-1609	(	_	_	_	_
13-22	1610-1616	TGF)-β	abstract	giv	_	_
13-23	1617-1625	released	_	_	_	_
13-24	1626-1630	from	_	_	_	_
13-25	1631-1637	glioma	abstract|object[90]	giv|giv[90]	coref|coref|coref|coref	13-32[94_90]|17-21|13-32[94_90]|17-21
13-26	1638-1642	stem	plant|object[90]	new|giv[90]	coref	13-33
13-27	1643-1648	cells	object[90]	giv[90]	_	_
13-28	1649-1650	(	_	_	_	_
13-29	1651-1655	GSCs	place	new	coref	17-37
13-30	1656-1657	)	_	_	_	_
13-31	1658-1659	,	_	_	_	_
13-32	1660-1671	mesenchymal	animal|object[94]	giv|giv[94]	appos|appos	13-36[0_94]|13-36[0_94]
13-33	1672-1676	stem	plant|object[94]	giv|giv[94]	coref	15-6
13-34	1677-1682	cells	object[94]	giv[94]	_	_
13-35	1683-1684	(	_	_	_	_
13-36	1685-1689	MSCs	object	giv	coref	13-40[97_0]
13-37	1690-1691	)	_	_	_	_
13-38	1692-1693	,	_	_	_	_
13-39	1694-1697	and	_	_	_	_
13-40	1698-1705	myeloid	object|object[97]	new|giv[97]	coref|coref	15-1[103_97]|15-1[103_97]
13-41	1706-1711	cells	object[97]	giv[97]	_	_
13-42	1712-1721	recruited	_	_	_	_
13-43	1722-1724	by	_	_	_	_
13-44	1725-1732	hypoxia	substance	giv	_	_
13-45	1733-1734	.	_	_	_	_

#Text=The reverse is also essential for the formation of distant or disseminated tumor nodules .
14-1	1735-1738	The	abstract[99]	new[99]	_	_
14-2	1739-1746	reverse	abstract[99]	new[99]	_	_
14-3	1747-1749	is	_	_	_	_
14-4	1750-1754	also	_	_	_	_
14-5	1755-1764	essential	_	_	_	_
14-6	1765-1768	for	_	_	_	_
14-7	1769-1772	the	event[100]	new[100]	_	_
14-8	1773-1782	formation	event[100]	new[100]	_	_
14-9	1783-1785	of	event[100]	new[100]	_	_
14-10	1786-1793	distant	event[100]|object[102]	new[100]|new[102]	_	_
14-11	1794-1796	or	event[100]|object[102]	new[100]|new[102]	_	_
14-12	1797-1809	disseminated	event[100]|object[102]	new[100]|new[102]	_	_
14-13	1810-1815	tumor	event[100]|abstract|object[102]	new[100]|new|new[102]	coref	20-1
14-14	1816-1823	nodules	event[100]|object[102]	new[100]|new[102]	_	_
14-15	1824-1825	.	_	_	_	_

#Text=Stem cells , including cancer stem cells ( CSCs ) , are pluripotent and capable of self-renewal , like induced pluripotent stem ( iPS ) cells induced by the transcription factors Oct3/4 , Sox2 , c-Myc , and Klf4 or OCT4 , SOX2 , NANOG , and LIN28 .
15-1	1826-1830	Stem	object[103]	giv[103]	coref	15-13[0_103]
15-2	1831-1836	cells	object[103]	giv[103]	_	_
15-3	1837-1838	,	object[103]	giv[103]	_	_
15-4	1839-1848	including	object[103]	giv[103]	_	_
15-5	1849-1855	cancer	object[103]|abstract	giv[103]|giv	_	_
15-6	1856-1860	stem	object[103]|plant	giv[103]|giv	coref	15-20[110_0]
15-7	1861-1866	cells	object[103]	giv[103]	_	_
15-8	1867-1868	(	_	_	_	_
15-9	1869-1873	CSCs	organization	new	_	_
15-10	1874-1875	)	_	_	_	_
15-11	1876-1877	,	_	_	_	_
15-12	1878-1881	are	_	_	_	_
15-13	1882-1893	pluripotent	object	giv	coref	15-21
15-14	1894-1897	and	_	_	_	_
15-15	1898-1905	capable	_	_	_	_
15-16	1906-1908	of	_	_	_	_
15-17	1909-1921	self-renewal	abstract	new	_	_
15-18	1922-1923	,	_	_	_	_
15-19	1924-1928	like	_	_	_	_
15-20	1929-1936	induced	abstract[110]	giv[110]	appos	15-24[0_110]
15-21	1937-1948	pluripotent	object|abstract[110]	giv|giv[110]	_	_
15-22	1949-1953	stem	abstract[110]	giv[110]	_	_
15-23	1954-1955	(	_	_	_	_
15-24	1956-1959	iPS	object	giv	appos	15-26
15-25	1960-1961	)	_	_	_	_
15-26	1962-1967	cells	object	giv	coref	17-21[140_0]
15-27	1968-1975	induced	_	_	_	_
15-28	1976-1978	by	_	_	_	_
15-29	1979-1982	the	abstract[113]|abstract[114]	new[113]|new[114]	coref|coref	17-25[142_113]|17-25[142_113]
15-30	1983-1996	transcription	abstract[113]|abstract[114]	new[113]|new[114]	_	_
15-31	1997-2004	factors	abstract[113]|abstract[114]	new[113]|new[114]	_	_
15-32	2005-2011	Oct3/4	abstract[114]	new[114]	_	_
15-33	2012-2013	,	_	_	_	_
15-34	2014-2018	Sox2	abstract	new	_	_
15-35	2019-2020	,	_	_	_	_
15-36	2021-2026	c-Myc	abstract	new	_	_
15-37	2027-2028	,	_	_	_	_
15-38	2029-2032	and	_	_	_	_
15-39	2033-2037	Klf4	abstract	new	coref	16-9
15-40	2038-2040	or	_	_	_	_
15-41	2041-2045	OCT4	abstract	new	coref	16-4
15-42	2046-2047	,	_	_	_	_
15-43	2048-2052	SOX2	abstract	new	_	_
15-44	2053-2054	,	_	_	_	_
15-45	2055-2060	NANOG	place	new	coref	17-17
15-46	2061-2062	,	_	_	_	_
15-47	2063-2066	and	_	_	_	_
15-48	2067-2072	LIN28	abstract	new	_	_
15-49	2073-2074	.	_	_	_	_

#Text=The expression of OCT4 , MYC , and KLF4 increases with increasing malignancy in astrocytomas , whereas MYC expression slightly decreases in recurrent glioblastomas .
16-1	2075-2078	The	abstract[122]	new[122]	coref	16-18[129_122]
16-2	2079-2089	expression	abstract[122]	new[122]	_	_
16-3	2090-2092	of	abstract[122]	new[122]	_	_
16-4	2093-2097	OCT4	abstract[122]|abstract	new[122]|giv	coref	17-19[138_0]
16-5	2098-2099	,	abstract[122]	new[122]	_	_
16-6	2100-2103	MYC	abstract[122]|abstract	new[122]|new	coref	16-18
16-7	2104-2105	,	abstract[122]	new[122]	_	_
16-8	2106-2109	and	abstract[122]	new[122]	_	_
16-9	2110-2114	KLF4	abstract[122]|abstract	new[122]|giv	coref	17-11
16-10	2115-2124	increases	_	_	_	_
16-11	2125-2129	with	_	_	_	_
16-12	2130-2140	increasing	_	_	_	_
16-13	2141-2151	malignancy	abstract[126]	giv[126]	_	_
16-14	2152-2154	in	abstract[126]	giv[126]	_	_
16-15	2155-2167	astrocytomas	abstract[126]|abstract	giv[126]|new	_	_
16-16	2168-2169	,	_	_	_	_
16-17	2170-2177	whereas	_	_	_	_
16-18	2178-2181	MYC	abstract|abstract[129]	giv|giv[129]	_	_
16-19	2182-2192	expression	abstract[129]	giv[129]	_	_
16-20	2193-2201	slightly	_	_	_	_
16-21	2202-2211	decreases	_	_	_	_
16-22	2212-2214	in	_	_	_	_
16-23	2215-2224	recurrent	object[130]	new[130]	_	_
16-24	2225-2238	glioblastomas	object[130]	new[130]	_	_
16-25	2239-2240	.	_	_	_	_

#Text=Exposure to temozolomide ( TMZ ) increases the expression of KLF4 and reduces the expression of Nanog and OCT4 in glioma cells , indicating that stem cell factors , especially KLF4 , play pivotal roles in GSCs .
17-1	2241-2249	Exposure	abstract[131]	new[131]	_	_
17-2	2250-2252	to	abstract[131]	new[131]	_	_
17-3	2253-2265	temozolomide	abstract[131]|abstract	new[131]|giv	appos	17-5
17-4	2266-2267	(	_	_	_	_
17-5	2268-2271	TMZ	abstract	giv	_	_
17-6	2272-2273	)	_	_	_	_
17-7	2274-2283	increases	_	_	_	_
17-8	2284-2287	the	abstract[134]	new[134]	_	_
17-9	2288-2298	expression	abstract[134]	new[134]	_	_
17-10	2299-2301	of	abstract[134]	new[134]	_	_
17-11	2302-2306	KLF4	abstract[134]|abstract	new[134]|giv	_	_
17-12	2307-2310	and	_	_	_	_
17-13	2311-2318	reduces	_	_	_	_
17-14	2319-2322	the	abstract[136]	new[136]	coref	22-17[0_136]
17-15	2323-2333	expression	abstract[136]	new[136]	_	_
17-16	2334-2336	of	abstract[136]	new[136]	_	_
17-17	2337-2342	Nanog	abstract[136]|substance	new[136]|giv	_	_
17-18	2343-2346	and	abstract[136]	new[136]	_	_
17-19	2347-2351	OCT4	abstract[136]|abstract[138]	new[136]|giv[138]	_	_
17-20	2352-2354	in	abstract[136]|abstract[138]	new[136]|giv[138]	_	_
17-21	2355-2361	glioma	abstract[136]|abstract[138]|abstract|object[140]	new[136]|giv[138]|giv|giv[140]	coref|coref	18-30|18-30
17-22	2362-2367	cells	abstract[136]|abstract[138]|object[140]	new[136]|giv[138]|giv[140]	_	_
17-23	2368-2369	,	_	_	_	_
17-24	2370-2380	indicating	_	_	_	_
17-25	2381-2385	that	abstract[142]	giv[142]	appos	17-30[143_142]
17-26	2386-2390	stem	abstract[142]	giv[142]	_	_
17-27	2391-2395	cell	place|abstract[142]	giv|giv[142]	coref	18-23
17-28	2396-2403	factors	abstract[142]	giv[142]	_	_
17-29	2404-2405	,	_	_	_	_
17-30	2406-2416	especially	abstract[143]	giv[143]	_	_
17-31	2417-2421	KLF4	abstract[143]	giv[143]	_	_
17-32	2422-2423	,	_	_	_	_
17-33	2424-2428	play	_	_	_	_
17-34	2429-2436	pivotal	abstract[144]	new[144]	_	_
17-35	2437-2442	roles	abstract[144]	new[144]	_	_
17-36	2443-2445	in	_	_	_	_
17-37	2446-2450	GSCs	abstract	giv	coref	18-20
17-38	2451-2452	.	_	_	_	_

#Text=The most common GSC marker CD133 , also known as prominin-1 ( PROM1 ) , is used to isolate GSCs by fluorescence-activated cell sorting ( FACS ) in primary glioma tissues and the cell lines U87 and T98G .
18-1	2453-2456	The	object[148]	new[148]	_	_
18-2	2457-2461	most	object[148]	new[148]	_	_
18-3	2462-2468	common	object[148]	new[148]	_	_
18-4	2469-2472	GSC	place|object[148]	new|new[148]	coref	23-36
18-5	2473-2479	marker	abstract|object[148]	new|new[148]	_	_
18-6	2480-2485	CD133	object[148]	new[148]	_	_
18-7	2486-2487	,	_	_	_	_
18-8	2488-2492	also	_	_	_	_
18-9	2493-2498	known	_	_	_	_
18-10	2499-2501	as	_	_	_	_
18-11	2502-2512	prominin-1	_	_	_	_
18-12	2513-2514	(	_	_	_	_
18-13	2515-2520	PROM1	abstract	new	_	_
18-14	2521-2522	)	_	_	_	_
18-15	2523-2524	,	_	_	_	_
18-16	2525-2527	is	_	_	_	_
18-17	2528-2532	used	_	_	_	_
18-18	2533-2535	to	_	_	_	_
18-19	2536-2543	isolate	_	_	_	_
18-20	2544-2548	GSCs	abstract	giv	coref	21-8
18-21	2549-2551	by	_	_	_	_
18-22	2552-2574	fluorescence-activated	abstract[152]	new[152]	appos	18-26[0_152]
18-23	2575-2579	cell	place|abstract[152]	giv|new[152]	coref	18-34
18-24	2580-2587	sorting	abstract[152]	new[152]	_	_
18-25	2588-2589	(	_	_	_	_
18-26	2590-2594	FACS	abstract	giv	_	_
18-27	2595-2596	)	_	_	_	_
18-28	2597-2599	in	_	_	_	_
18-29	2600-2607	primary	place[155]	giv[155]	_	_
18-30	2608-2614	glioma	abstract|place[155]	giv|giv[155]	coref	19-7
18-31	2615-2622	tissues	place[155]	giv[155]	_	_
18-32	2623-2626	and	place[155]	giv[155]	_	_
18-33	2627-2630	the	place[155]|abstract[157]	giv[155]|new[157]	_	_
18-34	2631-2635	cell	place[155]|place|abstract[157]	giv[155]|giv|new[157]	coref	20-22
18-35	2636-2641	lines	place[155]|abstract[157]	giv[155]|new[157]	_	_
18-36	2642-2645	U87	place[155]|abstract[157]|place	giv[155]|new[157]|new	_	_
18-37	2646-2649	and	place[155]|abstract[157]	giv[155]|new[157]	_	_
18-38	2650-2654	T98G	place[155]|abstract[157]|event	giv[155]|new[157]|new	_	_
18-39	2655-2656	.	_	_	_	_

#Text=There are changes in metabolism in glioma and oxidative phosphorylation , glycolysis , and glutaminolysis replace redox balance , bioenergetics , and biosynthesis , respectively .
19-1	2657-2662	There	_	_	_	_
19-2	2663-2666	are	_	_	_	_
19-3	2667-2674	changes	abstract[160]	giv[160]	_	_
19-4	2675-2677	in	abstract[160]	giv[160]	_	_
19-5	2678-2688	metabolism	abstract[160]|abstract[161]	giv[160]|new[161]	_	_
19-6	2689-2691	in	abstract[160]|abstract[161]	giv[160]|new[161]	_	_
19-7	2692-2698	glioma	abstract[160]|abstract[161]|abstract|substance[164]	giv[160]|new[161]|giv|new[164]	coref|coref	20-21|20-21
19-8	2699-2702	and	abstract[160]|abstract[161]|substance[164]	giv[160]|new[161]|new[164]	_	_
19-9	2703-2712	oxidative	abstract[160]|abstract[161]|person|substance[164]	giv[160]|new[161]|new|new[164]	_	_
19-10	2713-2728	phosphorylation	abstract[160]|abstract[161]|substance[164]	giv[160]|new[161]|new[164]	_	_
19-11	2729-2730	,	abstract[160]|abstract[161]	giv[160]|new[161]	_	_
19-12	2731-2741	glycolysis	abstract[160]|abstract[161]|substance	giv[160]|new[161]|new	_	_
19-13	2742-2743	,	_	_	_	_
19-14	2744-2747	and	_	_	_	_
19-15	2748-2762	glutaminolysis	_	_	_	_
19-16	2763-2770	replace	_	_	_	_
19-17	2771-2776	redox	object|abstract[167]	new|new[167]	coref|coref	20-18[175_167]|20-18[175_167]
19-18	2777-2784	balance	abstract[167]	new[167]	_	_
19-19	2785-2786	,	_	_	_	_
19-20	2787-2800	bioenergetics	substance	new	_	_
19-21	2801-2802	,	_	_	_	_
19-22	2803-2806	and	_	_	_	_
19-23	2807-2819	biosynthesis	substance	new	_	_
19-24	2820-2821	,	_	_	_	_
19-25	2822-2834	respectively	_	_	_	_
19-26	2835-2836	.	_	_	_	_

#Text=Tumor progression is enhanced by inflammation , which is an emerging hallmark of cancers that depends on the balance of glioma cell proliferation , migration , and escape from the immune system .
20-1	2837-2842	Tumor	abstract|abstract[171]	giv|giv[171]	_	_
20-2	2843-2854	progression	abstract[171]	giv[171]	_	_
20-3	2855-2857	is	_	_	_	_
20-4	2858-2866	enhanced	_	_	_	_
20-5	2867-2869	by	_	_	_	_
20-6	2870-2882	inflammation	abstract	new	_	_
20-7	2883-2884	,	_	_	_	_
20-8	2885-2890	which	_	_	_	_
20-9	2891-2893	is	_	_	_	_
20-10	2894-2896	an	abstract[173]	new[173]	_	_
20-11	2897-2905	emerging	abstract[173]	new[173]	_	_
20-12	2906-2914	hallmark	abstract[173]	new[173]	_	_
20-13	2915-2917	of	abstract[173]	new[173]	_	_
20-14	2918-2925	cancers	abstract[173]|abstract	new[173]|new	_	_
20-15	2926-2930	that	_	_	_	_
20-16	2931-2938	depends	_	_	_	_
20-17	2939-2941	on	_	_	_	_
20-18	2942-2945	the	abstract[175]	giv[175]	_	_
20-19	2946-2953	balance	abstract[175]	giv[175]	_	_
20-20	2954-2956	of	abstract[175]	giv[175]	_	_
20-21	2957-2963	glioma	abstract[175]|abstract|abstract[178]	giv[175]|giv|new[178]	coref|coref	23-31|23-31
20-22	2964-2968	cell	abstract[175]|place|abstract[178]	giv[175]|giv|new[178]	_	_
20-23	2969-2982	proliferation	abstract[175]|abstract[178]	giv[175]|new[178]	_	_
20-24	2983-2984	,	abstract[175]	giv[175]	_	_
20-25	2985-2994	migration	abstract[175]|event	giv[175]|new	_	_
20-26	2995-2996	,	_	_	_	_
20-27	2997-3000	and	_	_	_	_
20-28	3001-3007	escape	_	_	_	_
20-29	3008-3012	from	_	_	_	_
20-30	3013-3016	the	abstract[180]	new[180]	_	_
20-31	3017-3023	immune	abstract[180]	new[180]	_	_
20-32	3024-3030	system	abstract[180]	new[180]	_	_
20-33	3031-3032	.	_	_	_	_

#Text=However , the correlation between EMT and GSCs in glioblastoma has not been reported to date .
21-1	3033-3040	However	_	_	_	_
21-2	3041-3042	,	_	_	_	_
21-3	3043-3046	the	abstract[181]	new[181]	_	_
21-4	3047-3058	correlation	abstract[181]	new[181]	_	_
21-5	3059-3066	between	abstract[181]	new[181]	_	_
21-6	3067-3070	EMT	abstract[181]|abstract	new[181]|giv	coref	22-8
21-7	3071-3074	and	abstract[181]	new[181]	_	_
21-8	3075-3079	GSCs	abstract[181]|abstract	new[181]|giv	coref	22-10
21-9	3080-3082	in	abstract[181]	new[181]	_	_
21-10	3083-3095	glioblastoma	abstract[181]|object	new[181]|giv	coref	22-24
21-11	3096-3099	has	_	_	_	_
21-12	3100-3103	not	_	_	_	_
21-13	3104-3108	been	_	_	_	_
21-14	3109-3117	reported	_	_	_	_
21-15	3118-3120	to	_	_	_	_
21-16	3121-3125	date	time	new	_	_
21-17	3126-3127	.	_	_	_	_

#Text=In this study , we focused on EMT and GSCs and performed multivariable analyses using the expression data and OS in patients with glioblastoma .
22-1	3128-3130	In	_	_	_	_
22-2	3131-3135	this	abstract[186]	new[186]	_	_
22-3	3136-3141	study	abstract[186]	new[186]	_	_
22-4	3142-3143	,	_	_	_	_
22-5	3144-3146	we	person	acc	ana	23-11
22-6	3147-3154	focused	_	_	_	_
22-7	3155-3157	on	_	_	_	_
22-8	3158-3161	EMT	abstract	giv	_	_
22-9	3162-3165	and	_	_	_	_
22-10	3166-3170	GSCs	abstract	giv	_	_
22-11	3171-3174	and	_	_	_	_
22-12	3175-3184	performed	_	_	_	_
22-13	3185-3198	multivariable	abstract[190]	new[190]	_	_
22-14	3199-3207	analyses	abstract[190]	new[190]	_	_
22-15	3208-3213	using	_	_	_	_
22-16	3214-3217	the	abstract[192]	new[192]	_	_
22-17	3218-3228	expression	abstract|abstract[192]	giv|new[192]	_	_
22-18	3229-3233	data	abstract[192]	new[192]	_	_
22-19	3234-3237	and	_	_	_	_
22-20	3238-3240	OS	abstract	giv	_	_
22-21	3241-3243	in	_	_	_	_
22-22	3244-3252	patients	person[194]	giv[194]	coref	23-8[198_194]
22-23	3253-3257	with	person[194]	giv[194]	_	_
22-24	3258-3270	glioblastoma	person[194]|abstract	giv[194]|giv	_	_
22-25	3271-3272	.	_	_	_	_

#Text=To determine the distribution of survival of glioblastoma patients , we composed prognosis prediction formulae for the following components : epithelium ( EPI ) , mesenchyme ( MES ) , glioma ( GLI ) , GSC , molecular target therapy ( MTT ) genes , and potential glioma biomarkers ( PGBs ) .
23-1	3273-3275	To	_	_	_	_
23-2	3276-3285	determine	_	_	_	_
23-3	3286-3289	the	abstract[196]	new[196]	_	_
23-4	3290-3302	distribution	abstract[196]	new[196]	_	_
23-5	3303-3305	of	abstract[196]	new[196]	_	_
23-6	3306-3314	survival	abstract[196]|event[197]	new[196]|giv[197]	_	_
23-7	3315-3317	of	abstract[196]|event[197]	new[196]|giv[197]	_	_
23-8	3318-3330	glioblastoma	abstract[196]|event[197]|person[198]	new[196]|giv[197]|giv[198]	_	_
23-9	3331-3339	patients	abstract[196]|event[197]|person[198]	new[196]|giv[197]|giv[198]	_	_
23-10	3340-3341	,	_	_	_	_
23-11	3342-3344	we	person	giv	_	_
23-12	3345-3353	composed	_	_	_	_
23-13	3354-3363	prognosis	abstract|abstract[202]	giv|new[202]	_	_
23-14	3364-3374	prediction	event|abstract[202]	giv|new[202]	_	_
23-15	3375-3383	formulae	abstract[202]	new[202]	_	_
23-16	3384-3387	for	abstract[202]	new[202]	_	_
23-17	3388-3391	the	abstract[202]|abstract[203]	new[202]|new[203]	_	_
23-18	3392-3401	following	abstract[202]|abstract[203]	new[202]|new[203]	_	_
23-19	3402-3412	components	abstract[202]|abstract[203]	new[202]|new[203]	_	_
23-20	3413-3414	:	_	_	_	_
23-21	3415-3425	epithelium	abstract	new	_	_
23-22	3426-3427	(	_	_	_	_
23-23	3428-3431	EPI	abstract	new	_	_
23-24	3432-3433	)	_	_	_	_
23-25	3434-3435	,	_	_	_	_
23-26	3436-3446	mesenchyme	abstract	new	appos	23-28
23-27	3447-3448	(	_	_	_	_
23-28	3449-3452	MES	abstract	giv	_	_
23-29	3453-3454	)	_	_	_	_
23-30	3455-3456	,	_	_	_	_
23-31	3457-3463	glioma	abstract	giv	appos	23-33
23-32	3464-3465	(	_	_	_	_
23-33	3466-3469	GLI	abstract	giv	coref	23-48
23-34	3470-3471	)	_	_	_	_
23-35	3472-3473	,	_	_	_	_
23-36	3474-3477	GSC	abstract	giv	_	_
23-37	3478-3479	,	_	_	_	_
23-38	3480-3489	molecular	abstract[212]	new[212]	_	_
23-39	3490-3496	target	abstract|abstract[212]	new|new[212]	_	_
23-40	3497-3504	therapy	abstract[212]	new[212]	_	_
23-41	3505-3506	(	abstract[212]|abstract[214]	new[212]|new[214]	coref	24-3[218_214]
23-42	3507-3510	MTT	abstract[212]|abstract|abstract[214]	new[212]|new|new[214]	_	_
23-43	3511-3512	)	abstract[212]|abstract[214]	new[212]|new[214]	_	_
23-44	3513-3518	genes	abstract[212]|abstract[214]	new[212]|new[214]	_	_
23-45	3519-3520	,	_	_	_	_
23-46	3521-3524	and	_	_	_	_
23-47	3525-3534	potential	abstract[216]	new[216]	_	_
23-48	3535-3541	glioma	abstract|abstract[216]	giv|new[216]	_	_
23-49	3542-3552	biomarkers	abstract[216]	new[216]	_	_
23-50	3553-3554	(	_	_	_	_
23-51	3555-3559	PGBs	abstract	new	_	_
23-52	3560-3561	)	_	_	_	_
23-53	3562-3563	.	_	_	_	_

#Text=Consequently , several candidate genes were identified as promising glioblastoma predictors .
24-1	3564-3576	Consequently	_	_	_	_
24-2	3577-3578	,	_	_	_	_
24-3	3579-3586	several	abstract[218]	giv[218]	_	_
24-4	3587-3596	candidate	abstract[218]	giv[218]	_	_
24-5	3597-3602	genes	abstract[218]	giv[218]	_	_
24-6	3603-3607	were	_	_	_	_
24-7	3608-3618	identified	_	_	_	_
24-8	3619-3621	as	_	_	_	_
24-9	3622-3631	promising	_	_	_	_
24-10	3632-3644	glioblastoma	abstract[219]	new[219]	_	_
24-11	3645-3655	predictors	abstract[219]	new[219]	_	_
24-12	3656-3657	.	_	_	_	_
